OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial

Burosumab, a fully human IgG1 monoclonal antibody to FGF23, is approved in Canada and Brazil to treat XLH in patients ≥1 year of age and in the US to treat XLH in patients ≥6 months of age. Burosumab has also received conditional marketing authorization in Europe to treat XLH with radiographic evide...

Descripción completa

Detalles Bibliográficos
Autores principales: Perwad, Farzana, Portale, Anthony A, Carpenter, Thomas O, Briot, Karine, Imel, Erik Allen, Kamenicky, Peter, Weber, Thomas Joseph, Pitukcheewanont, Pisit, Cheong, Hae Il, De Beur, Suzanne Marie Jan, Imanishi, Yasuo, Ito, Nobuaki, Lachmann, Robin, Tanaka, Hiroyuki, Zhang, Lin, Skrinar, Alison, Rees, Linda, Insogna, Karl Leonard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Bone and Mineral Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209551/
http://dx.doi.org/10.1210/jendso/bvaa046.147

Ejemplares similares

Ejemplares similares